N
IONS icon

Natixis’s Ionis Pharmaceuticals IONS Stock Holding History

Natixis’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,087
Closed -$482K – 1222
2025
Q4 		$482K Sell
6,087
-139,199
-96% -$10.5M ﹤0.01% 848
2025
Q3 		$9.5M Buy
+145,286
New +$7.09M 0.04% 306
2025
Q1 		– Sell
-16,626
Closed -$581K – 1084
2024
Q4 		$581K Buy
+16,626
New +$621K ﹤0.01% 681
2024
Q3 		– Sell
-163
Closed -$7.77K – 1037
2024
Q2 		$7.77K Sell
163
-1,798
-92% -$73.7K ﹤0.01% 876
2024
Q1 		$85K Sell
1,961
-917
-32% -$43.7K ﹤0.01% 789
2023
Q4 		$146K Buy
+2,878
New +$138K ﹤0.01% 748
2023
Q1 		– Sell
-159,678
Closed -$6.03M – 1084
2022
Q4 		$6.03M Buy
159,678
+25,597
+19% +$1.08M 0.03% 349
2022
Q3 		$5.94M Buy
+134,081
New +$5.65M 0.03% 375
2022
Q1 		– Sell
-300,797
Closed -$9.15M – 1241
2021
Q4 		$9.15M Buy
+300,797
New +$9.47M 0.03% 418
2021
Q3 		– Sell
-8,530
Closed -$340K – 1241
2021
Q2 		$340K Buy
8,530
+2,871
+51% +$112K ﹤0.01% 773
2021
Q1 		$254K Buy
5,659
+1,792
+46% +$99.9K ﹤0.01% 1008
2020
Q4 		$219K Sell
3,867
-88,089
-96% -$4.39M ﹤0.01% 991
2020
Q3 		$4.36M Buy
91,956
+83,746
+1,020% +$4.65M 0.03% 297
2020
Q2 		$484K Buy
+8,210
New +$457K ﹤0.01% 622
2019
Q3 		– Sell
-99,891
Closed -$6.42M – 868
2019
Q2 		$6.42M Buy
99,891
+75,880
+316% +$5.36M 0.05% 281
2019
Q1 		$1.92M Buy
+24,011
New +$1.55M 0.01% 501
2018
Q2 		– Sell
-12,114
Closed -$534K – 932
2018
Q1 		$534K Buy
+12,114
New +$615K ﹤0.01% 663

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Natixis's IONS Position: Q1 2026 in Review

Natixis sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 6,087 shares — an estimated $482K sold.

Natixis first reported a position in IONS in Q1 2018 and held it in 17 quarters. The position peaked at $9.5M in Q3 2025. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Natixis reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 6,087 Ionis Pharmaceuticals shares in Q1 2026, an estimated $482K.
  • Natixis first reported a position in Ionis Pharmaceuticals in Q1 2018 and held it in 17 quarters.
  • Natixis's Ionis Pharmaceuticals position peaked at $9.5M in Q3 2025.
  • 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.